Quadruple adenine base–edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease–engineered T cells
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2427216122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Nils W Engel und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, T-Lymphocytes, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, US NIH, National Cancer Institute, Agilent Foundation (Agilent Technologies Foundation).
Abstract (Originalsprache)
Genome-editing technologies have enabled the clinical development of allogeneic cellular therapies, yet the optimal gene-editing modality for multiplex editing of therapeutic T cell product manufacturing remains elusive. In this study, we conducted a comprehensive comparison of CRISPR/Cas9 nuclease and adenine base editor (ABE) technologies in generating allogeneic chimeric antigen receptor (CAR) T cells, utilizing extensive in vitro and in vivo analyses. Both methods achieved high editing efficiencies across four target genes, critical for mitigating graft-versus-host disease and allograft rejection: TRAC or CD3E , B2M , CIITA , and PVR . Notably, ABE demonstrated higher manufacturing yields and distinct off-target profiles compared to Cas9, with translocations observed exclusively in Cas9-edited products. Functionally, ABE-edited CAR T cells exhibited superior in vitro effector functions under continuous antigen stimulation, including enhanced proliferative capacity and increased surface CAR expression. Transcriptomic analysis revealed that ABE editing resulted in reduced activation of p53 and DNA damage response pathways at baseline, along with sustained activation of metabolic pathways during antigen stress. Consistently, Assay for Transposase-Accessible Chromatin using sequencing data indicated that Cas9-edited, but not ABE-edited, CAR T cells showed enrichment of chromatin accessibility peaks associated with double-strand break repair and DNA damage response pathways. In a preclinical leukemia model, ABE-edited CAR T cells demonstrated improved tumor control and extended overall survival compared to their Cas9-edited counterparts. Collectively, these findings position ABE as superior to Cas9 nucleases for multiplex gene editing of therapeutic T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
- Agilent Research Laboratories, Santa Clara, CA 95051.
- Translational Center of Excellence in Hematopoietic Stem Cell Engineering, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104.
- Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
- Institute for Biomedical Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
ORCID-Profile: Daniel J Baker, Philipp C Rommel, Carl H June
Förderung
- NCI NIH HHS
- US NIH, National Cancer Institute
- Agilent Foundation (Agilent Technologies Foundation)
- Gilead | Kite Pharma
Zitieren
APA
Engel, N. W., Steinfeld, I., Ryan, D., Anupindi, K., Kim, S., Wellhausen, N., Chen, L., Wilkins, K., Baker, D. J., Rommel, P. C., Jarocha, D., Gohil, M., Zhang, Q., Milone, M. C., Fraietta, J. A., Davis, M., Young, R. M., & June, C. H. (2025). Quadruple adenine base–edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease–engineered T cells. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2427216122
Vancouver
Engel NW, Steinfeld I, Ryan D, Anupindi K, Kim S, Wellhausen N, et al. Quadruple adenine base–edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease–engineered T cells. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2427216122
BibTeX
@article{Engel2025,
author = {Engel, Nils W and Steinfeld, Israel and Ryan, Daniel and Anupindi, Kusala and Kim, Samuel and Wellhausen, Nils and Chen, Linhui and Wilkins, Katherine and Baker, Daniel J and Rommel, Philipp C and Jarocha, Danuta and Gohil, Mercy and Zhang, Qian and Milone, Michael C and Fraietta, Joseph A and Davis, Megan and Young, Regina M and June, Carl H},
title = {Quadruple adenine base–edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease–engineered T cells},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2427216122}
}
EUVIMED